EU Reports Highlight Urgency Of Rethinking Drug Investment And Procurement Reform
Medicines For Europe Has Called For Clearer Legal Guidance On Generic And Biosimilar Policies
Executive Summary
Medicines for Europe has responded to two recent publications from the European Commission, calling for policy reforms to support the role of generic and biosimilar medicines.
You may also be interested in...
Joined-Up Approach Must Underpin European Biosimilar Procurement
A more joined-up approach is needed on European procurement if the biosimilars market is to remain sustainable in the face of pricing and cost pressures, according to a discussion by industry stakeholders at Medicines for Europe’s 18th Biosimilar Medicines Conference.
New EU Rules Imminent On Joint Procurement Of Vaccines & Drugs In Health Crises
EU legislation just approved by legislators will require the European Commission to provide information on prices, manufacturers, delivery time frames and joint procurement processes for vaccines and medicines used in tackling future health crises such as pandemics.
Medicines For Europe Finds Inequitable Essential Medicines Access In CEE Countries
Countries across Central and Eastern Europe are failing to reap the full benefit of generic and biosimilar competition, according to a new report from Medicines for Europe.